Protafan NM is a human genetically engineered insulin that belongs to the group of intermediate-acting insulins. This drug is produced by two manufacturers - Novo Nordisk (Denmark) and Torrent Pharmaceutical (India). The international name of Protafana NM is human genetically modified insulin-isophame. Its synonyms include Biosulin N (Germany), Gansulin XN (Israel), Insuin Protafuan NM Penfil (USA), Insuin Humir N (Germany), Inhalan ntppx (France), Irotafan NM Penifleck (China) and Humisan Ppopflikl (Austria).
Protafan HM solution for injection is available in a concentration of 40 units/ml and suspension for injection in concentrations ranging from 42 units/0.4 ml to 1296 units/1 ml. In addition, the drug is available as an injection suspension (100 IU/ml).
Protafaon HM is an important component in the treatment of diabetic patients whose insulins do not work properly. It is prescribed for type 2 diabetes and other conditions in which insulin is needed to maintain blood glucose levels. It can be used alone or in combination with other medications to improve diabetes control.